Detection and Quantification of HspX Antigen in Sputum Samples Using Plasmonic Biosensing : Toward a Real Point-of-Care (POC) for Tuberculosis Diagnosis
Peláez Gutiérrez, Enelia Cristina (Institut Català de Nanociència i Nanotecnologia)
Estévez, M. Carmen (Institut Català de Nanociència i Nanotecnologia)
Mongui, Álvaro (Corporación CorpoGen)
Menéndez, M. Carmen (Universidad Autónoma de Madrid)
Toro, Carlos (Hospital Universitario La Paz (Madrid))
Herrera Sandoval, Oscar L. (Universidad Central)
Robledo, Jaime (Corporación para Investigaciones Biológicas)
García, María J. (Universidad Autónoma de Madrid)
Portillo, Patricia del (Corporación CorpoGen)
Lechuga, Laura M (Institut Català de Nanociència i Nanotecnologia)

Additional title:	Early diagnosis of Mycobacterium tuberculosis by detection and quantification of HspX antigen in sputum samples using plasmonic biosensing
Date:	2020
Abstract:	Advancements that occurred during the last years in the diagnosis of Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis infection, have prompted increased survival rates of patients. However, limitations related to the inefficiency of an early detection still remain; some techniques and laboratory methods do not have enough specificity and most instruments are expensive and require handling by trained staff. In order to contribute to a prompt and effective diagnosis of tuberculosis, we report the development of a portable, user-friendly, and low-cost biosensor device for its early detection. By using a label-free surface plasmon resonance (SPR) biosensor, we have established a direct immunoassay for the direct detection and quantification of the heat shock protein X (HspX) of Mtb, a well-established biomarker of this pathogen, directly in pretreated sputum samples. The method relies on highly specific monoclonal antibodies that are previously immobilized on the plasmonic sensor surface. This technology allows for the direct detection of the biomarker without amplification steps, showing a limit of detection (LOD) of 0. 63 ng mL-1 and a limit of quantification (LOQ) of 2. 12 ng mL-1. The direct analysis in pretreated sputum shows significant differences in the HspX concentration in patients with tuberculosis (with concentration levels in the order of 116-175 ng mL-1) compared with non-tuberculosis infected patients (values below the LOQ of the assay).
Grants:	Ministerio de Economía y Competitividad SEV-2017-0706
Rights:	Tots els drets reservats.
Language:	Anglès
Document:	Article ; recerca ; Versió sotmesa a revisió
Subject:	Tuberculosis diagnosis ; HspX recombinant protein ; SPR immunosensor ; Point-of-care device ; Human sputum samples
Published in:	ACS infectious diseases, Vol. 6, Issue 5 (May 2020) , p. 1110-1120, ISSN 2373-8227

DOI: 10.1021/acsinfecdis.9b00502

Preprint 24 p, 683.3 KB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Experimental sciences > Catalan Institute of Nanoscience and Nanotechnology (ICN2)
Articles > Research articles
Articles > Published articles